HOPO THERAPEUTICS, INC. - DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC

On Feb 25, 2026, Department of Health and Human Services obligated $9,369,524 to HOPO THERAPEUTICS, INC. for development of hopo-101 as an mcm (medical countermeasure) decorporation agent for the treatment of individuals with known or suspected internal contamination with radionuclides (the ?mcm indication?)…. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in BERKELEY, CA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.